Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

STEM CELL TREATMENT IN INDIA Why to chose stem cell treatment in India?

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 1 Perivenous distribution of multiple sclerosis lesions

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Paradoxical immune reconstitution inflammatory syndrome

Figure 2 The US Centers for Disease Control and

Figure 4 Host damage from infection-related inflammatory

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Nat. Rev. Neurol. doi: /nrneurol

Current Controversies in Multiple Sclerosis Management

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 1 Outline of the AHSCT procedure

Figure 5 Corticosteroid treatment can reduce brain

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 2 Proposed model of therapeutic mechanisms of AHSCT

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Poststroke plasticity and recovery

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Lifestyle and environmental factors affect

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 2 Diagnostic scheme for MSA

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 6 Combining population-wide and high-risk strategies

Figure 4 Implantable neuromodulation treatments

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Frequency of vertigo and dizziness syndromes

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Cellular pathways implicated in CIPN

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 Endovascular treatment in acute ischaemic stroke

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Figure Overview.

Figure Overview.

In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application Graça Almeida-Porada, Anthony.

Nat. Rev. Neurol. doi: /nrneurol

Figure 7 VEGF as a mediator of neuroinflammatory disease

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT, haematopoietic stem cell transplantation; KGF,

Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT, haematopoietic stem cell transplantation; KGF,

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.119 Figure 1 Overview of different MS measures in trajectory to treatment concepts Figure 1 | Overview of different MS measures in trajectory to treatment concepts. Cladribine is the most recent addition to the rising number of pulsed immune reconstitution therapies recommended for the treatment of highly active multiple sclerosis (MS). HSCT, haematopoietic stem cell transplantation. Wiendl, H. (2017) Cladribine — an old newcomer for pulsed immune reconstitution in MS Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.119